drugset / Trial / NCT07687875
Oncolytic Virotherapy to Enhance PReoperative IMmunotherapy Efficacy in Patients With Proficient Mismatch Repair (pMMR) Rectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Phase I clinical trial that will investigate the safety and tolerability of combining the modified vaccinia virus BT-001 with systemic pembrolizumab in patients with localised pMMR rectal cancer
Timeline
- Start
- 2026-06-17
- Primary completion
- 2028-12-31
- Completion
- 2033-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BT-001 | Unknown | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | — | Other |